Thetis Pharmaceuticals Receives Funding from the Crohn’s & Colitis Foundation to Support Investigational Mucosal Healing Therapy for Inflammatory Bowel Disease

Crohn’s & Colitis Foundation’s IBD Ventures award supports development of Thetis’ novel first-in-class Resolvin oral therapy (TP-317) for treatment of ulcerative colitis and Crohn’s disease BRANFORD, CT – (November 19, 2019) – Thetis Pharmaceuticals (“Thetis”), a biopharmaceutical company developing novel therapies for gastrointestinal diseases, today announced receipt of funding from the Crohn’s & Colitis Foundation’s […]

Thetis Pharmaceuticals Receives $2.3 Million NIH Grant to Advance Potential First-in-class Drug with Clinical Proof of Concept in NASH

BRANFORD, CT – (ACCESSWIRE – October 24, 2019) – Thetis Pharmaceuticals, a biopharmaceutical company developing novel therapies for treatment of gastrointestinal diseases, today announced the receipt of a Fast-Track Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH) for development of an innovative new therapy (TP-352) for non-alcoholic steatohepatitis (NASH), a […]

Thetis to Present at KRF Innovations Symposium on First-In-Class Resolvin-Based Drug Candidate for Inflammatory Bowel Disease

Resolvin E1 candidate (TP-317) represents a novel approach to treating inflammatory bowel disease based on activating inflammation resolution and tissue repair pathways that directly promote mucosal healing BRANFORD, CT – (July 13, 2019) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company with platform technology that is developing Resolvin-based therapies for inflammatory diseases, will be presenting […]

Thetis Pharmaceuticals Preclinical Data Shows Efficacy of TP-317 in Ulcerative Colitis and Crohn’s Disease Models with Unique Mucosal Healing Mechanism of Action

TP-317 represents a novel approach to treating inflammatory bowel disease (IBD) based on activating intrinsic resolution and repair pathways without compromising immune function BRANFORD, CT – (May 18, 2019) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company with platform technology developing a new class of Resolvin-based therapies for gastrointestinal inflammatory diseases, today announced preclinical data […]

Dr. Ronald Lennox Joins the Board of Directors of Thetis Pharmaceuticals as it Transitions into a Clinical Stage Biotechnology Company

BRANFORD, CT – (May 6, 2019) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company focused on novel gastrointestinal therapies that promote mucosal healing, announced today that Ron Lennox, D.Phil., has joined its Board of Directors. Dr. Lennox, a prolific biotechnology entrepreneur and investor over the last 30 years, will work with Thetis senior management as […]